.jpg?n=9025 "Vac Header")
Join vaccine leaders from around the world as they discuss critical issues surrounding the development of effective – and affordable – vaccines at the 5th annual “Novel Vaccines” meeting. This meeting not only provides a snapshot of where vaccine innovations stand today, but also gives vaccine professionals the opportunity to network, establish collaborations, and learn from leaders in the field. Be part of the information exchange in the quest to protect human health and advance the science of vaccines.
Opening Keynote Presentation:
FDA’s Approach Towards Pandemic Vaccine PreparednessDavid S. Cho, Ph.D., M.P.H., Senior Scientist, Emerging and Pandemic Threat Preparedness, Office of the Director, Center for Biologics Evaluation and Research (CBER), FDA
|
Influenza Virus-Like Particle Vaccine Produced in Insect Cells Elicits Hemagglutination and Neuraminidase Inhibiting Antibodies in Immunized Healthy Adults
Steven Pincus, Ph.D., Executive Director, Analytical Operations, Novavax, Inc.
New Pneumococcal Vaccines: Protein, Conjugate and Hybrid Vaccine Strategies
Mark Alderson, Ph.D., M.B.A., Director, Pneumococcal Vaccine Project, PATH
Removing the Roadblock to an HIV Vaccine
Philip R. Johnson, M.D., Professor of Pediatrics, Director, Joseph Stokes Research Institute, The Children’s Hospital of Philadelphia, CSO & Executive VP, The Children’s Hospital of Philadelphia
Development of an HIV Vaccine: Challenges and Successes
Indresh Srivastava, Ph.D., Associate Director, Vaccines Research, Protein Biochemistry, Novartis Vaccines & Diagnostics, Inc.
Live Attenuated Pre-Eythrocytic Malaria Vaccines
Sebastian A. Mikolajczak, Ph.D., Staff Scientist, Malaria Program, Seattle Biomedical Research Institute
Development of a Metabolically Active Non-Replicating Sporozoite Vaccine to Prevent Malaria Caused By Plasmodium Falciparum
Peter Billingsley, Ph.D., Senior Director, Entomology and Quality Systems, Sanaria
TB Vaccine Development
Jerald C. Sadoff, M.D., President and CEO, Aeras Global TB Vaccine Foundation
Talk Title to be Announced
Beth-Ann Coller, Ph.D., Senior Vice President, Research and Development, Hawaii Biotech, Inc.
Immunotherapy for Prostate Cancer: Explaining the Conundrum of Improved Survival without Improvement in Time to Progression
James Gulley, M.D., Ph.D., Director, Clinical Trials Group, Laboratory of Tumor Immunology and Biology, The Center for Cancer Research (CCR), National Cancer Institute, NIH
Carbohydrate Tumor Antigen Vaccines Using Unique Strategies
Kate Rittenhouse-Olson, Ph.D., Professor, Director, Biotechnology Program, Biotechnical and Clinical Laboratory Sciences, The University at Buffalo
Novel Strategies for Synthetic Vaccines by Mimicry of Discontinuous Epitopes and Multivalency
Rob M.J. Liskamp, Ph.D., Professor, Medicinal Chemistry and Chemical Biology, Utrecht University
Filamentous Phage as a Carrier for Conjugate Vaccines
Jamie Scott, Ph.D., Professor, Molecular Biology & Biochemistry, Simon Fraser University
“Universal” Influenza Vaccine: Progress and Challenges
Hersh Mehta, Ph.D., Head, Product Conception and Development, Sanofi Pasteur Biologics
Epitope-Based Immunome-Derived Vaccines: A Strategy for Improved Design and Safety
Annie De Groot, Ph.D., CEO, Immunology, EpiVax, Inc.
On the Path to the Clinic: Rapid Discovery of Protective T Cell Antigenic Targets from Naturally Infected Humans
Mojca Skoberne, Ph.D., Head, Cellular Immunology, Genocea Biosciences
Development of a New Generation of Adenovirus (Ad5) Vaccines
Raj Dua, Ph.D., VP, Operations, Product Development, Etubics Corporation
How to overcome Cold Chain Challenges
Tim Redmond, Director, Regional Accounts, World Courier, Inc.